[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.173.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
November 20, 2002

Sertraline for Treatment of Depression in Acute Coronary Syndromes—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior Editor

 

Not Available

JAMA. 2002;288(19):2403. doi:10.1001/jama.288.19.2403-JLT1120-1-3

In Reply: In response to Drs Lespérance and Frasure-Smith, a power analysis suggested that a very large sample would be required to detect adverse cardiac events, and such a trial would have been unethical without preliminary safety and efficacy data. Lespérance and Frasure-Smith are also concerned about the validity of the depression outcome data because of potential unblinding due to adverse events. We disagree that independent raters, rather than treating physicians, are better to ensure blindness. Such concerns are unrealistic in this population. The average patient receiving placebo was receiving 11 other medications as well, and thus the physician was often unable to determine which medication was causing a patient's complaint.

First Page Preview View Large
First page PDF preview
First page PDF preview
×